51 results about "Vaccine efficacy" patented technology

The invention discloses a high-throughput antigen-specific T cell detection method based on mass spectrum flow cytometry. The invention belongs to the technical field of biology, and particularly relates to a high-throughput antigen-specific T cell detection method based on mass spectrum flow cytometry. According to the present invention, the activation induction marker (AIM) technology and the intracellular cytokine staining (ICS) are integrated, and the CyTOF platform is combined to achieve gt; 20 parameters are synchronously detected, and multiple activation-induction marker double positive markers, multifunctional cytokine spectrums (IFN-gamma, TNF-alpha, GZMB, IL-2 and the like) and immune memory phenotypes (CD45RA / CCR7) are covered. The standardized detection scheme provides a high-dimensional and quantifiable biomarker combination for vaccine protection efficacy evaluation, and has important clinical application value.

The invention relates to the technical field of biological medicine, in particular to stably expressed porcine pseudorabies virus gD recombinant protein, a vaccine composition and a preparation method and application of the vaccine composition. The invention provides a porcine pseudorabies virus gD recombinant protein capable of being stably expressed. The amino acid sequence of the porcine pseudorabies virus gD recombinant protein is shown as SEQ ID NO: 7. The porcine pseudorabies virus gD recombinant protein is stably expressed in monoclonal cells, the passage frequency is stable, and when 48 generations are continuously passed, the porcine pseudorabies virus gD recombinant protein still has good protein expression quantity. And a good foundation is laid for subsequent application in preparation of a stable porcine pseudorabies subunit vaccine composition or a porcine pseudorabies virus vaccine potency test preparation.

The invention discloses application of a broad-spectrum influenza virus polypeptide vaccine in preparation of a medicine for preventing influenza virus infection and controlling influenza virus reinfection, and belongs to the technical field of biological medicine. The vaccine is designed on the basis of artificially synthesized polypeptide, a polypeptide sequence which is highly conservative and has immunocompetence is screened and optimized aiming at various subtype influenza virus proteins, a broad-spectrum polypeptide vaccine P125-H is constructed, and an Ii-Key technology and an MF59 adjuvant are applied to enhance immune response. The vaccine can effectively induce immune protection against H1N1 and H7N9 influenza A viruses, significantly reduce the virus load, reduce pathological injury to the lung and improve the survival rate. The P125-H vaccine is composed of three optimized polypeptides, has a cross protection effect on various influenza virus subtypes, has the potential of being developed into a broad-spectrum influenza vaccine, and provides a new technical scheme for coping with influenza virus variation and improving vaccine efficacy.

Disclosed herein are protein-based compositions and conjugates thereof that can take advantage of beneficial delivery properties to improve vaccine efficacy. An example protein-based composition includes an albumin-binding nanobody and a peptide antigen domain. An example conjugate includes the protein-based composition attached to a drug through a linker. Also disclosed are methods of making and using the protein-based compositions and conjugates thereof.

Provided are a difference quantification comparison method for an adaptive immune system, and the use thereof. The method comprises obtaining at least one of a BCR heavy chain sequence of a B cell, a BCR light chain sequence of the B cell and a TCR β chain sequence of a T cell of a sample to undergo comparison, and sequencing same; comparing the determined sequence with a gene sequence in the IMGT database to obtain sequence annotation information of the corresponding sequence, and further constructing a 3D graph displaying the adaptive immune condition of the sequence; then by means of using a minimum transformation cost method, quantifying an immune state difference between samples to be tested and between a sample to be tested and the database that has undergone the test. The method for quantifying immune differences can be used for evaluating the immune state of biological samples, and can also be used for evaluating influences of various therapy and intervention methods on the immune system, so as to judge the effects of the therapies and interventions, including but not limited to the drug efficacy, the vaccine efficacy, etc.

The present invention is a multivalent immunogenic composition for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent immunogenic composition are protein-based, DNA-based, or a combination thereof. This invention also provides a method and kit for detecting a filarial nematode and determining vaccine efficacy.

An effective treatment method for a broad variety of diseases in both animals and humans is disclosed. The method includes combining one or more vaccines with a treatment compound to enhance vaccine efficacy. The disclosed treatment compound does not act directly on the pathogen, and thus the organisms cannot readily develop resistance to the treatment. When a compound such as, but not limited to, the disclosed compound is used in conjunction with one or more vaccines, a synergistic effect is realized. The suggested compound is derived from a lipopolysaccharide (LPS) of gram negative bacteria. The treatment compound is combined with one or more appropriate vaccines and is administered early in the life of an animal to achieve a synergistic effect compared with the use of the treatment compound or the vaccine alone.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The invention discloses an mRNA (messenger Ribonucleic Acid) vector for in-vitro transcription as well as a construction method and application thereof, and relates to the technical field of gene engineering, and the technical key point is that the mRNA vector comprises the following gene segments: 5 'UTR (Untranslated Region), signal peptide, 3' UTR and polyadenylate tail; 5 'UTR is 70 nt or Ces1d; the signal peptide is Igk or tPAP22A; the 3 'UTR is ApoA-II or AP3B1; the polyadenylic acid is PolyA (40 + 10 + 60) or PolyA (30 + 10 + 70); the invention further provides a construction method of the mRNA vector recombinant plasmid, a cell containing the mRNA vector, a recombinant bacterium containing the mRNA vector, and an application of the mRNA vector, the cell and the recombinant bacterium in in-vitro transcription. According to the mRNA vaccine vector provided by the invention, by optimizing the vector element, the stability and translation efficiency of the vector element can be improved, meanwhile, the vaccine efficacy is improved, and an important technical support is provided for future vaccine development and disease prevention and control.

The invention discloses an immunogenic composition containing gE virus-like nanoparticles as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE virus-like nanoparticles comprise VZV gE, a linker peptide (SGS) and a VZV gI polypeptide containing a Th epitope. The immunogenic composition provided by the invention can be applied to VZV vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is better than that of Xinanliei, the use of an immunopotentiator is reduced, and the clinical side reaction is lower. In addition, the vaccine can also induce an obvious gI specific antibody, which is beneficial for further improving the effectiveness of the vaccine. In short, the immunogenic composition provided by the invention has good clinical application potential.

The invention discloses a canine parvovirus CPV-2c subtype virus strain and application thereof, and relates to the technical field of biology. The canine parvovirus CPV-2c subtype virus strain is preserved in the China Center for Type Culture Collection on November 12, 2024, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: V202492. Genetic evolution analysis shows that the canine parvovirus CPV-2c subtype virus strain obtained through separation has a better genetic relationship with other epidemic strains published domestically. The strain has good pathogenicity, can show typical CPV clinical symptoms when infected dogs, has great advantages for verifying therapeutic drugs and evaluating vaccine efficacy in vivo, and plays an important role in research and development of the therapeutic drugs and vaccines. In addition, the strain can be cultured and proliferated in vitro and has the potential of being developed into vaccines.

The invention belongs to the technical field of biology, and particularly relates to a recombinant monoclonal antibody of sheep anti-bluetongue virus VP7 protein. A sheep anti-bluetongue virus antibody library is obtained through a single cell V (D) J sequencing technology, a sheep anti-bluetongue virus VP7 protein recombinant monoclonal antibody is screened and successfully expressed, and it is identified through indirect ELISA and cellular immunofluorescence experiments that the recombinant monoclonal antibody has high affinity with bluetongue virus and can be specifically combined with VP7 protein. The recombinant monoclonal antibody is used as a competitive antibody to establish a competitive ELISA detection method aiming at the bluetongue virus VP7 protein, high specificity of bluetongue antibody detection can be realized, and a basis is provided for mastering the epidemiology of bluetongue virus and evaluating the immune effect of vaccines.

The present invention relates to: an adjuvant composition for vaccine, comprising galectin-4 as an active ingredient, which, when administered together with an antigen, can improve antibody titer and enhance cellular immunity and humoral immunity; a vaccine composition comprising galectin-4 and an antigen; a method for promoting immune responses, comprising a step of administering the adjuvant composition for a vaccine to a subject together with the vaccine composition or before and after the administration of the vaccine composition; and a vaccine adjuvant composition for promoting immune responses, comprising galectin-4. The adjuvant composition for a vaccine, of the present invention, can increase antibody titer produced by an antigen and can increase both humoral and cellular immune responses, and thus can increase vaccine efficacy, can reduce the production cost of a vaccine by reducing the usage amount of antigen, and is expected to be applicable to cancer treatment vaccines.

Provided herein are engineered T-celi receptors (TCRs) having nanomoiar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV / A2 presentation on the surface of cells.

Methods and compositions for monitoring mutation burden, cancer status, vaccine efficacy using cell-free DNA sequencing following enrichment with combination probe panels are disclosed.

The invention belongs to the technical field of biological medicine, and relates to a dendritic cell vaccine as well as a preparation method and application thereof, in particular to a dendritic cell vaccine based on enhancement of dendritic cell maturation and vaccine efficiency and application of the dendritic cell vaccine in tumor treatment. The dendritic cell disclosed by the invention is a dendritic cell with deletion of a metabotropic glutamate receptor 4 or a dendritic cell treated by forskolin, and the dendritic cell can promote the expression of co-stimulatory molecules on the surface of the dendritic cell; the proliferation of T cells is promoted; inducing the effector T cells to secrete interferon gamma and granzyme B; the killing capability of T cells on tumor cells is enhanced. The dendritic cell vaccine disclosed by the invention comprises dendritic cells loaded with antigens, wherein the antigens are liver cancer cell lysates. The dendritic cell vaccine disclosed by the invention has an anti-tumor effect and can be used for preparing anti-tumor medicines.

The present invention discloses a construction method and application of a self-replicating mRNA vaccine for porcine epidemic diarrhea virus, belonging to the field of pharmaceutical technology. The self-replicating mRNA vaccine comprises the sequence as set forth in SEQ ID NO: 1. Also disclosed is a lipid nanoparticle-encapsulated self-replicating mRNA vaccine, which comprises the self-replicating mRNA vaccine and lipids for encapsulating the self-replicating mRNA vaccine. The mRNA vaccine prepared by the present invention can quickly respond to the currently prevalent porcine epidemic diarrhea virus, reducing the R & D and production cycle of new vaccine development. Vaccine efficacy tests show that the self-replicating mRNA vaccine prepared by the present invention has good immunogenicity and can produce high levels of neutralizing antibodies against porcine epidemic diarrhea virus in vivo.

Methods and systems for the multiple detection and / or measurement of biomarkers in a sample are provided herein. These methods and systems can be used for rapid disease detection and / or monitoring, monitoring of vaccine efficacy and immune response, monitoring of therapeutic agents, and / or monitoring of the safety and efficacy of treatments.

Age-related thymic involution is a major cause of immunosenescence, characterized by reduced T-cell production, resulting in increased susceptibility to cancers, infections, autoimmunity and reduced vaccine efficacy. RANK / RANKL axis in the thymus is altered during aging and endothelial cells (EC) depend on RANK for their cellularity and functional maturation. Decreased RANKL availability during aging results in a decline in cellularity and function of EC and thymic epithelial cells (TEC) leading to thymic involution. Whereas RANKL neutralization in young mice mimics thymic involution, RANKL cytokine treatment in aged mice restores thymic architecture, EC and TEC cellularity and functional properties. Consequently, RANKL improves T-cell progenitor homing to the thymus and boosts T-cell production. This cascade of events results in peripheral T-cell renewal and effective anti-tumor and vaccine responses. RANKL stimulates EC and TEC in human thymic organo-cultures and is the basis of a treatment that rejuvenates thymic function and improves T-cell immunity in the elderly.

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The application belongs to the technical field of biotechnology and relates to the field of veterinary diagnosis, and particularly discloses a liquid-phase blocking ELISA kit for porcine Senecavirus neutralizing antibody, which contains porcine Senecavirus single-domain antibody and matched detection reagents, and the porcine Senecavirus single-domain antibody can also be an antigen-binding fragment of the single-domain antibody, the single-domain antibody is selected from one or more groups in 52 groups, the heavy chain variable region of each group of single-domain antibodies or antigen-binding fragments contains CDR-1, CDR-2 and CDR-3, the amino acid sequences of the heavy chain variable region CDR-1 (VH-CDR-1) of the 52 groups of single-domain antibodies or antigen-binding fragments are respectively shown in SEQ ID NO. 1-SEQ ID NO. 52, the amino acid sequences of the heavy chain variable region CDR-2 (VH-CDR-2) are respectively shown in SEQ ID NO. 53-SEQ ID NO. 104, and the amino acid sequences of the heavy chain variable region CDR-3 (VH-CDR-3) are respectively shown in SEQ ID NO. 105-SEQ ID NO. 156. The kit can quickly detect the SVA neutralizing antibody level in serum, has high sensitivity, good specificity and stable results, and can be better applied to SVA vaccine efficacy evaluation.

The present invention provides an organelle-targeted molecular in situ assembly chimera and its application, belonging to the field of molecular technology. The chimera of the present invention comprises, from N-terminus to C-terminus, an organelle-residence structural unit, an assembly structural unit, a tracer structural unit, and a monomeric streptavidin structural unit, each of which is connected by a linker. The chimera constructed by the present invention assembles biological functional molecules in situ in the organelle region and is applied to various vaccine antigen models. It can significantly enhance antigen-specific immune responses in various vaccine antigen models, improve vaccine efficacy, and enhance the immune protection generated by the vaccine.

The invention discloses a method for rapidly quantifying Seneca virus inactivated antigen protein. The method comprises the following steps: establishing a specific purification technology to obtain a Seneca antigen standard substance, and establishing a linear relation equation between the Seneca antigen content and the chromatographic peak area; meanwhile, a pretreatment method for samples which are not suitable for direct sample loading detection in the Seneca inactivated vaccine production process is established, so that the samples which can be used for detection are obtained; further, in order to eliminate the influence of the target protein loss on the detection result in the sample treatment process, determining the sample recovery rate R in different treatment processes through a labeling recovery test; and finally, through a linear equation and the recovery rate R, calculating to obtain the antigen content of the sample at each stage in the Seneca inactivated vaccine production process. The method is used for directly detecting the content of the Seneca inactivated antigen protein, has the advantages of simple detection operation process and high detection result repeatability, is suitable for each stage of the Seneca inactivated vaccine production process, and can effectively control the Seneca inactivated vaccine production process and the vaccine efficacy.

The present disclosure is directed to dopamine producing probiotics to increase immune responses to vaccination and to provide increased immune protection. The present disclosure is further directed to dopamine producing synbiotic compositions, formulations, plants, and synthetic compounds and their use for targeted clinical and veterinary applications, for example, in promoting health and well-being and enhancing vaccine efficacy. The present disclosure also provides an approach for optimization of synbiotic delivery of a probiotic or other dopamine producing product with a dopamine precursor to beneficially aid in the use of such products for a variety of conditions and diseases, and particularly in the field of vaccines, whether prophylactic or therapeutic.

Aspects of the present disclosure relate to functionalized polymers and methods of use thereof. Certain aspects are directed to polymers comprising adjuvants for use in stimulating an immune response. In some cases, provided are polymers comprising inflammasome activators, in some cases also comprising a TLR agonist, which may be formulated in a pharmaceutical composition. Also disclosed are methods for improving vaccine efficacy and immunotherapy efficacy. Certain aspects relate to compositions and methods for stimulation of CD4+ and / or CD8+ T cell responses in a subject.

This invention discloses a high-affinity mouse anti-eel IgM monoclonal antibody, a hybridoma cell line, and its applications. The mouse anti-eel IgM monoclonal antibody comprises a heavy chain variable region and a light chain variable region. The CDR region of the heavy chain variable region contains three sequences as shown in SEQ ID NO. 1-3, and the CDR region of the light chain variable region contains three sequences as shown in SEQ ID NO. 4-6. The mouse anti-eel IgM monoclonal antibody can be secreted by the hybridoma cell line ArIgMH-33G9D2G7C12, with accession number CCTCC NO: C202545. The mouse anti-eel IgM monoclonal antibody provided by this invention can be used for flow cytometry to identify eel IgM. + This monoclonal antibody, developed for B cells, can be used for the specific detection of secretory IgM in eels via ELISA and Western blot. It exhibits high specificity, sensitivity, and affinity, making it suitable for structural analysis of eel IgM and detection of immune response levels. This lays the foundation for in-depth research on the eel immune system and the establishment of methods for evaluating vaccine efficacy using antibody levels as an indicator.

The invention provides an organelle-targeted molecule in-situ assembly chimera and application thereof, and belongs to the technical field of molecules. The chimera sequentially comprises an organelle residing structural unit, an assembling structural unit, a tracing structural unit and a monomer streptomycin structural unit from an N end to a C end, and all the units are connected through linkers. According to the chimera constructed by the invention, the biological functional molecules are assembled in an organelle area in situ and are applied to various vaccine antigen models, so that the immunoreaction of antigen specificity in the various vaccine antigen models can be remarkably enhanced, the vaccine efficacy is improved, and the immune protection generated by the vaccine is enhanced.

The present invention addresses the problem of providing, as an antibody titer-improving agent (e.g., an adjuvant) that continues the effect of vaccination by vaccines or the like, a safe, simple and economical antibody titer-improving agent (e.g., an adjuvant) that can be easily ingested by all ages, and a method for producing the same. The present invention relates to a method for increasing antibody titer and a method for enhancing the effect of a vaccine using Lactobacillus bulgaricus OLL1073R-1 or a culture thereof, and an antibody titer increasing agent, such as an adjuvant, comprising Lactobacillus bulgaricus OLL1073R-1 or a culture thereof.

Methods and compositions are disclosed for monitoring mutational load, cancer status, and vaccine efficacy using cell-free DNA sequencing after enrichment with combinatorial probe panels.

Methods and compositions are disclosed for monitoring mutation load, cancer status, vaccine potency with cell-free DNA sequencing following enrichment with a combined set of probes.